Zobrazeno 1 - 10 of 107 pro vyhledávání: '"Herma H. Fidder"'
1
Akademický článek
Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease
Autor: Femke M. Prins, Iwan J. Hidding, Marjolein A.Y. Klaassen, Valerie Collij, Johannes P.D. Schultheiss, Werna T.C. Uniken Venema, Amber Bangma, Jurne B. Aardema, Bernadien H. Jansen, Wout G.N. Mares, Ben J.M. Witteman, Eleonora A.M. Festen, Gerard Dijkstra, Marijn C. Visschedijk, Herma H. Fidder, Arnau Vich Vila, Bas Oldenburg, Ranko Gacesa, Rinse K. Weersma
Publikováno v: Gut Microbes, Vol 16, Iss 1 (2024)
Emerging evidence suggests the gut microbiome’s potential in predicting response to biologic treatments in patients with inflammatory bowel disease (IBD). In this prospective study, we aimed to predict treatment response to vedolizumab and ustekinu
Externí odkaz: https://doaj.org/article/75c0bb382cf0416fa8df443a241eb914
Zobrazit plný text záznamu
2
A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis
Autor: Maartje M. van de Meeberg, Renske C. F. Hebing, Michael T. Nurmohamed, Herma H. Fidder, Martijn W. Heymans, Gerd Bouma, Marjolein S. de Bruin‐Weller, Janneke Tekstra, Bart van den Bemt, Robert de Jonge, Maja Bulatović Ćalasan
Publikováno v: van de Meeberg, M M, Hebing, R C F, Nurmohamed, M T, Fidder, H H, Heymans, M W, Bouma, G, de Bruin-Weller, M S, Tekstra, J, van den Bemt, B, de Jonge, R & Bulatović Ćalasan, M 2023, ' A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis ', British Journal of Clinical Pharmacology, vol. 89, no. 1, pp. 61-79 . https://doi.org/10.1111/bcp.15579
British Journal of Clinical Pharmacology, 89, 61-79
British Journal of Clinical Pharmacology, 89, 1, pp. 61-79
Contains fulltext : 291154.pdf (Publisher’s version ) (Open Access) AIMS: In immune-mediated inflammatory diseases (IMIDs), early symptom control is a key therapeutic goal. Methotrexate (MTX) is the first-line treatment across IMIDs. However, MTX i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7af0925734264262034ac1205557a46
https://hdl.handle.net/2066/291154
Zobrazit plný text záznamu
3
Akademický článek
Development and validation of a diverticular clinical score for symptomatic uncomplicated diverticular disease after acute diverticulitis in a prospective patient cohort
Autor: Adi Lahat, Herma H Fidder, Shomron Ben-Horin
Publikováno v: Therapeutic Advances in Gastroenterology, Vol 13 (2020)
Background: Following an attack of acute diverticulitis (AD), many patients continue to suffer from a complex of symptoms, titled ‘symptomatic uncomplicated diverticular disease (SUDD)’. To date, there is no validated clinical score for standardi
Externí odkaz: https://doaj.org/article/319c3d2883004122afc61cd94d7d6caf
Zobrazit plný text záznamu
5
Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease
Autor: Remi Mahmoud, Edo H.J. Savelkoul, Wout Mares, Rogier Goetgebuer, Ben J.M. Witteman, Daan B. de Koning, Sebastiaan A.C. van Tuyl, Itta Minderhoud, Maurice W.M. D. Lutgens, Dilek Akol-Simsek, Fiona D.M. van Schaik, Herma H. Fidder, Jeroen M. Jansen, Petra G.A. van Boeckel, Nofel Mahmmod, Carmen S. Horjus-Talabur Horje, Tessa E.H. Römkens, Jean-Frédéric Colombel, Frank Hoentjen, Bindia Jharap, Bas Oldenburg
Publikováno v: Clinical Gastroenterology and Hepatology, 21, 3, pp. 750-760.e4
Clinical Gastroenterology and Hepatology, 21(3), 750-760.e4. W.B. Saunders
Clinical Gastroenterology and Hepatology, 21, 750-760.e4
Contains fulltext : 291394.pdf (Publisher’s version ) (Open Access) BACKGROUND & AIMS: Discontinuation of anti-tumor necrosis factor-α treatment (anti-TNF) (infliximab and adalimumab) in patients with inflammatory bowel disease (IBD) is associated
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ba6229d4e93f40aa5dba971b240530c
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/291394
Zobrazit plný text záznamu
6
Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease
Autor: Bindia Jharap, Nofel Mahmmod, Bas Oldenburg, Michiel T. van der Kaaij, J Schultheiss, Boris P. van Hellemondt, J Louwers, Petra G van Boeckel, Herma H. Fidder, Remi Mahmoud
Publikováno v: Alimentary Pharmacology & Therapeutics. 54:1298-1308
BACKGROUND Inflammatory bowel disease (IBD) is often managed with anti-tumour necrosis factor-α therapy (anti-TNFα), but treatment efficacy is compromised by high annual rates of loss of response (13%-21% per patient-year). AIMS To assess whether t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::097f1891a7891acec973f1bcd06f28ff
https://doi.org/10.1111/apt.16605
Zobrazit plný text záznamu
8
Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events
Autor: Bas A. C. van Tuyl, Marieke Pierik, Vera E. R. Asscher, P W Jeroen Maljaars, Bas Oldenburg, Anniek M. van der Aalst, Andrea E. van der Meulen-de Jong, Dutch Icc, Eelco C. Brand, Nofel Mahmmod, Karen van der Aalst, Herma H. Fidder, Quirine M.J. van der Vliet
Publikováno v: International Journal of Colorectal Disease
International Journal of Colorectal Disease, 35(12), 2331-2338. SPRINGER
International Journal of Colorectal Disease, 35(12), 2331-2338. Springer, Cham
Purpose To assess safety and effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in IBD patients ≥ 60 years. Methods Ninety IBD patients ≥ 60 years at initiation of anti-TNF therapy, 145 IBD patients ≥ 60 years without anti-TNF thera
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e38666bfc82218187a355af8fde9b48b
https://cris.maastrichtuniversity.nl/en/publications/e92f6606-f495-47b1-9535-c069cf7f826d
Zobrazit plný text záznamu
9
Akademický článek
Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.
Autor: Mirthe E van der Valk, Marie-Josée J Mangen, Mirjam Severs, Mike van der Have, Gerard Dijkstra, Ad A van Bodegraven, Herma H Fidder, Dirk J de Jong, C Janneke van der Woude, Mariëlle J L Romberg-Camps, Cees H M Clemens, Jeroen M Jansen, Paul C van de Meeberg, Nofel Mahmmod, Andrea E van der Meulen-de Jong, Cyriel Y Ponsioen, Clemens Bolwerk, J Reinoud Vermeijden, Peter D Siersema, Max Leenders, Bas Oldenburg, COIN study group and the Dutch Initiative on Crohn and Colitis
Publikováno v: PLoS ONE, Vol 11, Iss 4, p e0142481 (2016)
With the increasing use of anti-TNF therapy in inflammatory bowel disease (IBD), a shift of costs has been observed with medication costs replacing hospitalization and surgery as major cost driver. We aimed to explore the evolution of IBD-related cos
Externí odkaz: https://doaj.org/article/a65838c5657347abb0fa1aa8abe71eed
Zobrazit plný text záznamu
10
Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container
Autor: Sandra Altena, Herma H. Fidder, Max R. Clevers, Johannes P. D. Schultheiss, Bindia Jharap, Dominique Baas
Publikováno v: Digestive Diseases and Sciences
Background Adherence to adalimumab in inflammatory bowel disease (IBD) patients is reported to be below par. Non-adherence may result in loss-of-response and increased hospitalization. We analyzed the effect of an electronic needle container (ENC) on
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bd9568a3171f86dbee7ab43ed2a7fb1
https://doi.org/10.1007/s10620-020-06395-z
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje